Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Staar Surgical (STAA) stock in plain English

Free brief · no signupStart here
STAAPublished Nov 19, 2026
Staar Surgical Co
Healthcare · Medical Instruments & Supplies
Manufactures implantable lenses that eye surgeons insert to correct nearsightedness and astigmatism without removing natural tissue.
Assets:
Monrovia facilityManufacturing site in California produces proprietary biocompatible lenses
Nidau operationsPackaging and distribution site based in Switzerland
EVO lens familyCore product line generating most ophthalmic implant revenue
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

78
OPS ScoreOperating finances
Latest quote
-1.26%$25.03
$1.26B
n/a
$328.08M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was STAA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Staar Surgical (STAA) do?

Staar Surgical Co (STAA) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures implantable lenses that eye surgeons insert to correct nearsightedness and astigmatism without removing natural tissue. Produces specialized implantable lenses made from proprietary collagen material to correct refractive vision conditions. It is worth $1.26B on the market and sold $328.08M over the last year.

Market cap
$1.26B
Annual sales
$328.08M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 19, 2026

Brands and businesses behind STAA

  • EVO ICL: Sells implantable phakic contact lenses directly to ophthalmic surgeons and clinics for vision correction.
  • Visian ICL: Provides implantable collamer lenses globally for correcting severe nearsightedness, farsightedness, and astigmatism.
  • Collamer: Proprietary biocompatible collagen copolymer material used across all company manufactured implantable optical devices.

STAA’s flags, in plain English

Each flag is a number from Staar Surgical’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Stupid Cash

Can pay this year's bills 4.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 9% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 71.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Heavily Shorted

12% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about STAA

How big is Staar Surgical?

Staar Surgical’s market cap is $1.26B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $328.08M: what customers paid the company over the last year, before any costs.

What could go wrong with STAA?

A major portion of sales comes from China, making operational revenue highly vulnerable to shifts in local consumer spending and regulatory policies. That is one risk on Staar Surgical’s card. Its first risk flag is Heavily Shorted, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Staar Surgical’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. STAA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card